Any news on advancements in Parkinson's disease treatments or medication
Community
HealthYour question
Any news on advancements in Parkinson's disease treatments or medication
AI search focus (disambiguated)
New advancements, clinical trial breakthroughs, FDA approvals, or newly announced medications and treatments for Parkinson's disease.
Tags
Update found
Review the latest finding below. Monitoring keeps running; you’ll be notified again if something materially changes. Stop monitoring when you no longer want alerts.
Latest from the web
On 22 June 2026, several advancements in Parkinson's disease treatment were announced, including Brenig Therapeutics' data on BT-409, an AI-designed NLRP3 inhibitor that targets neuroinflammation by crossing the blood-brain barrier. Scenic Biotech joined the LITE program to test PLA2G15 inhibitors for LRRK2-related Parkinson's, and a new study from IRBLleida demonstrated that combining virtual reality with brain stimulation (tDCS) significantly improves patient balance. Additionally, the University of Delaware established the DCNR3 research center to accelerate discoveries in neurologic recovery and Parkinson's care.
- Brenig Therapeutics BT-409 Data: On 22 June 2026, Brenig announced data for BT-409, an AI-designed NLRP3 inhibitor that crosses the blood-brain barrier to target neuroinflammation in Parkinson's disease.
- Scenic Biotech LITE Program: Scenic Biotech joined the LRRK2 Investigative Therapeutics Exchange (LITE) on 22 June 2026 to advance PLA2G15 inhibitors as a potential disease-modifying treatment for Parkinson's.
- VR and Brain Stimulation Study: A study published on 22 June 2026 by IRBLleida showed that a rehabilitation program combining virtual reality with transcranial direct current stimulation (tDCS) significantly improves balance and gait in Parkinson's patients.
- DCNR3 Research Center: The University of Delaware established the Delaware Center for Neurologic Rehabilitation & Recovery Research (DCNR3) on 22 June 2026 to accelerate Parkinson's and stroke research.
Sources (2)
Monitoring stays on automatically. Clear highlight when you’re done reading (optional). Snooze or stop monitoring below if you prefer.